Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition
The DOI matches its Crossref record.
Abstract
BACKGROUND: Patients with atherosclerotic renovascular disease (ARVD) are almost invariably treated by revascularization. However, the long-term outcomes of this approach on survival and progression to renal failure have not been investigated and have not been compared with that of a purely medical treatment. The aim of this observational study was to investigate factors affecting long-term (over 5 years) outcome, survival and renal function of patients with ARVD treated invasively or medically. METHODS: ARVD was demonstrated angiographically in 195 patients who were consecutively enrolled into a follow-up study. Patient age was 65.6+/-11.2 years, serum creatinine was 1.74+/-1.22 mg/dl and renal artery lumen narrowing was 73.5+/-17.5%. A revascularization was performed in 136 patients, whereas 54 subjects having comparable characteristics were maintained on a medical treatment throughout the study; five patients were lost during follow-up. RESULTS: The main follow-up was 54.4+/-40.4 months. The assessment of cardiovascular survival and renal survival at the end of follow-up revealed 46 cardiovascular deaths, 20 patients with end-stage renal disease (ESRD) and 41 patients with an increase in serum creatinine of over one-third. The multivariate analysis showed that renal revascularization did not affect mortality or renal survival compared with medical treatment. Revascularization produced slightly lower increases in serum creatinine and a better control of blood pressure. A longer survival was associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) (P = 0.002) in both revascularized and medically treated patients. The only significant predictor of ESRD was an abnormal baseline serum creatinine. CONCLUSIONS: On long-term follow-up, ARVD was associated with a poor prognosis due to a high cardiovascular mortality and a high rate of ESRD. In our non-randomized study, revascularization was not a major advantage over medical treatment in terms of mortality or renal survival. The use of ACEIs was associated with improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- Harding MB, Smith LR, Himmelstein SI et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol1992; 2: 1608–1616 · DOI · Paper page
- van Ampting JMA, Penne EL, Beek FJA et al. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant2003; 18: 1147–1151 · DOI
- Losito A, Fagugli RM, Zampi I et al. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens1996; 9: 1062–1067 · DOI
- Harden PN, Mac Leod MJ, Rodger RSC et al. Effect of renal artery stenting on progression of renovascular renal failure. Lancet1997; 349: 1133–1136 · DOI · Paper page
- Webster J, Marshall F, Abdalla M et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens1998; 12: 329–335 · DOI · Paper page
- van Jaarsveld, Krijnen P, Pieterman H et al. the effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med2000; 342: 1007–1014 · DOI · Paper page
- Nordmann AJ, Woo K, Parkes R, Logan A. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med2003;114: 44–50 · DOI · Paper page
- Ives N, Wheatley K, Stowe RL et al. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant2003; 18: 298–304 · DOI · Paper page
- Conlon PJ, Athirakul K, Kovalik E et al. Survival in renovascular disease. J Am Soc Nephrol1998; 9: 252–256 · DOI · Paper page
- Wright JR, Shurrab AE, Cheung C et al. A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis2002; 39: 1153–1161 · DOI
- Plouin PF, Chatellier G, Darnè B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Hypertension1998; 31: 823–829 · DOI · Paper page
- Ramos F, Kotliar C, Alvarez D et al. Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int2003; 63: 276–282 · DOI
- Chabova V, Schirger A, Stanson A, Mc Kusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc2000; 75: 437–444 · DOI · Paper page
- Scoble JE, Maher ER, Hamilton J, Dick R, Sweny P, Moorehead JF. Atherosclerotic renovascular disease causing renal impairment—a case for treatment. Clin Nephrol1989; 31: 119–122
- Losito A, Gaburri M, Errico R, Parente B, Cao PG. Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol1999; 52: 339–343
- Caps MT, Zierler RE, Polissar NL et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int1998; 53: 735–742 · DOI · Paper page
- Wright JR, Duggal A, Thomas R et al. Clinicopathological correlation in biopsy proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant2001; 16: 765–770 · doi:10.1093/ndt/16.4.765
- Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol2004; 15: 1974–1982 · DOI · Paper page
- Losito A, Parente B, Cao PG, Jeffery S, Afzal A. ACE gene polymorphism and survival in atherosclerotic renovascular disease. Am J Kidney Dis2000; 35: 211–215 · doi:10.1016/s0272-6386(00)70328-3
- Hricik DE, Browning PG, Kopelman R et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med1983; 308: 373–376 · DOI · Paper page
- Textor S. ACE inhibitors in renovascular hypertension. Cardiovasc Drugs Ther1990; 4: 229–235 · DOI
- Khong TK, Missouris CG, Belli AM et al. Regression of atherosclerotic renal artery stenosis with aggressive lipid lowering therapy. J Hum Hypertens2001; 15: 431–433 · DOI
Cited by
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.07.018 · Cited by 963
Halliday, A., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 651
Koelemay, M. J., Geelkerken, R. H., Kärkkäinen, J., Leone, N., Antoniou, G. A., de Bruin, J. L., Gombert, A., Gottsätter, A., Iborra, E., Ronchey, S., et al. (2025) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2025.06.010 · Cited by 123
Metadata
- Authors
- Losito, A., Errico, R., Santirosi, P., Lupattelli, T., Scalera, G. B., & Lupattelli, L.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-03
- Volume
- 20
- Issue
- 8
- Pages
- 1604-1609
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2171223472
- Cited by
- 119
- References
- 0
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. https://app.cochat.ai/papers/10.1093/ndt/gfh865
- The paper
- Losito, A., Errico, R., Santirosi, P., Lupattelli, T., Scalera, G. B., & Lupattelli, L. (2005). Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfh865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.